Anxo Pharmaceutical Co., Ltd.
Anxo Pharmaceutical Co., Ltd., a specialty pharmaceutical company, develops, manufactures, and sells pharmaceutical products for medical professionals and patients in Taiwan and internationally. The company offers prescription and over the counter drugs in various therapeutic areas, such as cardiovascular, metabolism, CNS, diabetic, respiratory, anti-infection, dermatology, nephrology, urology, o… Read more
Anxo Pharmaceutical Co., Ltd. - Asset Resilience Ratio
Anxo Pharmaceutical Co., Ltd. (6677) has an Asset Resilience Ratio of 1.27% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Anxo Pharmaceutical Co., Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Anxo Pharmaceutical Co., Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$25.98 Million | 1.27% |
| Total Liquid Assets | NT$25.98 Million | 1.27% |
Asset Resilience Insights
- Limited Liquidity: Anxo Pharmaceutical Co., Ltd. maintains only 1.27% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Anxo Pharmaceutical Co., Ltd. Industry Peers by Asset Resilience Ratio
Compare Anxo Pharmaceutical Co., Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Anxo Pharmaceutical Co., Ltd. (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Anxo Pharmaceutical Co., Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.13% | NT$23.91 Million | NT$2.11 Billion | -4.08pp |
| 2023-12-31 | 5.22% | NT$115.73 Million | NT$2.22 Billion | +4.17pp |
| 2022-12-31 | 1.05% | NT$20.70 Million | NT$1.97 Billion | +0.24pp |
| 2021-12-31 | 0.81% | NT$15.54 Million | NT$1.92 Billion | +0.04pp |
| 2020-12-31 | 0.77% | NT$14.78 Million | NT$1.91 Billion | -- |